Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib

Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib

Ceritinib resulted in a significant, durable response of a metastatic inflammatory myofibroblastic tumor (IMT) after failure of crizotinib. A chromoplectic TPM3–ALK rearrangement involving many known oncogenes was found in the residual IMT. Ceritinib may be useful for patients with IMT after failure...

Full description

Bibliographic Details
Main Authors: Mansfield, A. S., Murphy, S. J., Harris, F. R., Robinson, S. I., Marks, R. S., Johnson, S. H., Smadbeck, J. B., Halling, G. C., Yi, E. S., Wigle, D., Vasmatzis, G., Jen, J.
Format: Online
Language:English
Published: Oxford University Press 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091324/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5091324/

Similar Items